20260420_Reta_5MG.png
20260420_Reta_10MG.png
20260420_Reta_20MG.png
20260420_Reta_5MG.png
20260420_Reta_10MG.png
20260420_Reta_20MG.png

Retatrutide

from $115.00

Full Name: Retatrutide (LY3437943)

CAS Number: 2381089-83-2

Molecular Formula: C₂₇₅H₄₁₅N₇₅O₈₃S₂

Molecular Weight: 6,376 g/mol (approximate)

Appearance: White lyophilized powder

Solubility: Water-soluble (pH-dependent)

Storage: -20°C, desiccated, protected from light

Size:

Full Name: Retatrutide (LY3437943)

CAS Number: 2381089-83-2

Molecular Formula: C₂₇₅H₄₁₅N₇₅O₈₃S₂

Molecular Weight: 6,376 g/mol (approximate)

Appearance: White lyophilized powder

Solubility: Water-soluble (pH-dependent)

Storage: -20°C, desiccated, protected from light

Research Context

Retatrutide (LY3437943) is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — the first molecule to engage all three incretin/glucagon receptors. Developed by Eli Lilly, it represents the frontier of multi-receptor peptide pharmacology and is currently in Phase 3 clinical trials.

For researchers, retatrutide is significant as the most structurally complex incretin analog in the current pipeline, providing an advanced case study in multi-target peptide design. Its three-receptor activity profile makes it a uniquely valuable tool for studying the interplay between GIP, GLP-1, and glucagon signaling pathways.

Key References

  1. Coskun T, et al. (2022). "LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist." Cell Metab. 34(9):1234-1247.e9. PMID: 36070752

  2. Jastreboff AM, et al. (2023). "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." N Engl J Med. 389(6):514-526. PMID: 37385268